ERBB2 and breast cancer: The APT trial, a non-randomized open-label phase 2 trial with comprehensive 10-year follow-up, has validated the safety and efficacy of trastuzumab combined with weekly Paclitaxel in managing small, node-negative HER2-positive breast cancer [39].